- Home
- QSI vs GNLX Comparison
QSI vs GNLX Comparison
Compare QSI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- GNLX
- Stock Information
- Founded
- QSI 2013
- GNLX 2001
- Country
- QSI United States
- GNLX United States
- Employees
- QSI N/A
- GNLX N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- GNLX Health Care
- Exchange
- QSI Nasdaq
- GNLX Nasdaq
- Market Cap
- QSI 214.3M
- GNLX 184.4M
- IPO Year
- QSI N/A
- GNLX 2023
- Fundamental
- Price
- QSI $1.26
- GNLX $2.96
- Analyst Decision
- QSI Strong Buy
- GNLX Strong Buy
- Analyst Count
- QSI 3
- GNLX 4
- Target Price
- QSI $3.42
- GNLX $17.75
- AVG Volume (30 Days)
- QSI 2.7M
- GNLX 138.3K
- Earning Date
- QSI 05-15-2025
- GNLX 05-06-2025
- Dividend Yield
- QSI N/A
- GNLX N/A
- EPS Growth
- QSI N/A
- GNLX N/A
- EPS
- QSI N/A
- GNLX N/A
- Revenue
- QSI $3,058,000.00
- GNLX N/A
- Revenue This Year
- QSI $151.18
- GNLX N/A
- Revenue Next Year
- QSI $172.07
- GNLX N/A
- P/E Ratio
- QSI N/A
- GNLX N/A
- Revenue Growth
- QSI 182.63
- GNLX N/A
- 52 Week Low
- QSI $0.61
- GNLX $1.60
- 52 Week High
- QSI $5.77
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- QSI 51.74
- GNLX 54.28
- Support Level
- QSI $1.15
- GNLX $2.26
- Resistance Level
- QSI $1.35
- GNLX $3.06
- Average True Range (ATR)
- QSI 0.07
- GNLX 0.31
- MACD
- QSI 0.02
- GNLX 0.04
- Stochastic Oscillator
- QSI 64.71
- GNLX 78.42
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.